Dr. Fred A Furia, MD Internal Medicine - Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 21 Marple Rd, Haverford, PA 19041 Phone: 610-649-7692 |
News Archive
Access to Care After Massachusetts' Health Care Reform: A Safety Net Hospital Patient Survey - Policy analysts have long said that Massachusetts and its 2006 health reform law provide great insight into the federal health law and how its expansion of insurance coverage will play out.
Intelerad Medical Systems will be featuring its hospital solutions at the AHRA 2010 Annual Meeting and Exposition on August 22 to 26, 2010 in Washington, DC.
"Now that we know how the body defends itself against the Chlamydia bacteria, we can develop a vaccine that optimises that defence. We have a basic understanding of how the vaccine could work, but some work remains to be done. We believe that it will take a few years before the vaccine becomes a reality," says researcher Ellen Marks, the author of the thesis.
Zacharon Pharmaceuticals, Inc. today announced that the company has entered into a strategic research collaboration with Pfizer Inc. to develop drugs for orphan diseases, including lysosomal storage disorders. The potential value of the collaboration to Zacharon is approximately USD $210 million. The collaboration includes the potential development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.
Results from a two-year retrospective cohort study presented at the 63rd Annual Meeting of the American Academy of Neurology, Hawaii, U.S., showed that patients were significantly more likely to develop cardiovascular conditions, including hypertension, cardiac dysrhythmias and chronic ischemic heart diseases after an initial diagnosis of RLS, as compared to controls without RLS.
› Verified 4 days ago